The positive Phase 1b data de-risks ANB033's mechanism and supports the broader pipeline (EoE, vitiligo). Key catalysts ahead: Cohort 2 data Q1 2027, EoE data Q3 2027, and Phase 2 starts in H1 2027.
Price Chart
Executive Summary
First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b gluten-challenge trial in celiac disease. ANB033 met all key histologic and symptom endpoints with statistical significance and a favorable safety profile, supporting advancement into late-stage development in 2027.
Key Facts
- ANB033 achieved a statistically significant protective effect on gluten-induced intestinal damage and symptoms vs placebo.
- LS mean change in Vh:Cd ratio: -0.17 on ANB033 vs -0.66 on placebo, +0.49 placebo-adjusted delta (p=0.009).
- LS mean change in IEL density: -1.20 on ANB033 vs +18.83 on placebo, -20.03 placebo-adjusted delta (p<0.001).
- ANB033 prevented symptom increase throughout the 14-day gluten challenge; CDSD score statistically significant from day 1 through day 7.
- No serious adverse events, no severe AEs, and no AEs leading to discontinuation on ANB033.
- Company anticipates starting a late-stage clinical trial in celiac disease in 2027.
- Cohort 2 (mucosal healing) enrollment completing imminently, top-line data expected Q1 2027.
- Phase 1b in eosinophilic esophagitis enrolling 50 patients, top-line data expected Q3 2027.
- Phase 2 development in vitiligo and one additional indication expected to initiate in H1 2027.
- ANB033 has received FDA Fast Track designation from the FDA.
Financial Impact
No financial data not provided; clinical-stage biotech with no revenue from approved products.
Risk Factors
- Phase 1b data is early-stage; late-stage trials may fail to replicate results.
- No approved therapeutic option for celiac disease; regulatory path is uncertain.
- Company is pre-revenue and likely requires additional financing to fund late-stage development.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-419761 |
| Document: trax-20261012.htm | 0001193125-26-419761 |
| Document: 0001193125-26-419761-index-headers.html | 0001193125-26-419761 |
| Document: 0001193125-26-419761-index.html | 0001193125-26-419761 |
| Document: 0001193125-26-419761.txt | 0001193125-26-419761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers